Laura K. Thompson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Laura K. Thompson has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Amy M. Berkman
Department of Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
7 shared publications - Caryn Lerman
USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California
7 shared publications - David Robert Freyer
Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA
7 shared publications - Jorge J. Nieva
Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
7 shared publications - Michael E. Roth
Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
7 shared publications - Michelle Tran
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California
7 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by IOP Publishing in Environmental Research: Health
- Vol. 4 (1) , 015011
Duration of agricultural pesticide exposure application and Parkinson’s disease in California’s central valley
While numerous pesticides have been linked to Parkinson’s disease (PD), few studies have evaluated the long-term effects of ambient exposure to the wide range of pesticides used in commercial agriculture across multiple decades and exposure windows. We examined the contribution of exposure duration and timing to PD risk in 829 PD patients and 824 controls enrolled in California’s Central Valley. Using a validated geospatial model integrating California pesticide use reporting and land-use data, we quantified proximity-based ambient pesticide applications at residential and workplace addresses for 287 pesticides applied within 500 m of at least 25 participants’ locations between 1974 and 10 years prior to the index year (diagnosis for cases, enrollment for controls, 1998–2016). The exposure duration was calculated as the proportion of eligible years with any nearby application. Unconditional logistic regression models (false discovery rate (FDR)-corrected) estimated exposure effects for each pesticide on PD risk, and constrained distributed lag models evaluated associations across time windows before diagnosis. Longer exposure duration to 56 pesticides was associated with increased PD risk (FDR < 0.05), with odds ratios ranging from 1.10 to 1.25 per standard deviation increase in exposure. Among these, 34 overlapped with pesticides previously identified using an intensity-based metric. Endothall showed the strongest association (OR = 1.27, 95% CI: 1.16–1.39). Associations were generally stronger for exposures occurring 11–20 or 21–30 years prior to diagnosis. These findings indicate that prolonged exposure duration to specific pesticides is relevant to PD risk and suggest latency periods of two to three decades for several agents.
- 1 March 2026
- Published by IOP Publishing in Environmental Research: Health
- Vol. 4 (1) , 015011
Open AccessDuration of agricultural pesticide exposure application and Parkinson’s disease in California’s central valley
While numerous pesticides have been linked to Parkinson’s disease (PD), few studies have evaluated the long-term effects of ambient exposure to the wide range of pesticides used in commercial agriculture across multiple decades and exposure windows. We examined the contribution of exposure duration and timing to PD risk in 829 PD patients and 824 controls enrolled in California’s Central Valley. Using a validated geospatial model integrating California pesticide use reporting and land-use data, we quantified proximity-based ambient pesticide applications at residential and workplace addresses for 287 pesticides applied within 500 m of at least 25 participants’ locations between 1974 and 10 years prior to the index year (diagnosis for cases, enrollment for controls, 1998–2016). The exposure duration was calculated as the proportion of eligible years with any nearby application. Unconditional logistic regression models (false discovery rate (FDR)-corrected) estimated exposure effects for each pesticide on PD risk, and constrained distributed lag models evaluated associations across time windows before diagnosis. Longer exposure duration to 56 pesticides was associated with increased PD risk (FDR < 0.05), with odds ratios ranging from 1.10 to 1.25 per standard deviation increase in exposure. Among these, 34 overlapped with pesticides previously identified using an intensity-based metric. Endothall showed the strongest association (OR = 1.27, 95% CI: 1.16–1.39). Associations were generally stronger for exposures occurring 11–20 or 21–30 years prior to diagnosis. These findings indicate that prolonged exposure duration to specific pesticides is relevant to PD risk and suggest latency periods of two to three decades for several agents.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Figure 2 shows overall 5-year survival curves by subsequent malignant neoplasm (SMN) type from SMN diagnosis among those with primary adolescent and young adult (AYA) (a) female breast cancer, (b) cervical/uterine cancer, (c) Hodgkin lymphoma who were diagnosed between 1998 and 2020 (California Cancer Registry Data). Shaded areas represent 95% confidence intervals.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Figure 2 shows overall 5-year survival curves by subsequent malignant neoplasm (SMN) type from SMN diagnosis among those with primary adolescent and young adult (AYA) (a) female breast cancer, (b) cervical/uterine cancer, (c) Hodgkin lymphoma who were diagnosed between 1998 and 2020 (California Cancer Registry Data). Shaded areas represent 95% confidence intervals.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Table 2 shows treatments received by subsequent malignant neoplasm status.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Table 2 shows treatments received by subsequent malignant neoplasm status.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Background:Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized.Methods:Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry (n = 251,632). Pearson’s χ2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN.Results:A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither.Conclusions:Lung SMN has a long latency and high mortality among survivors of AYA cancer.Impact:More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Background:Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized.Methods:Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry (n = 251,632). Pearson’s χ2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN.Results:A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither.Conclusions:Lung SMN has a long latency and high mortality among survivors of AYA cancer.Impact:More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Figure 1 shows the cumulative incidence over time of developing subsequent malignant neoplasm (SMN) among survivors of primary adolescent and young adult (AYA) (a) female breast cancer who developed lung (n = 112) and non-lung (n = 4,971) SMN, (b) cervical/uterine cancer who developed lung (n = 95) and non-lung (n = 1,451) SMN, (c) Hodgkin lymphoma who developed lung (n = 70) and non-lung (n = 1,129) and who were diagnosed with a primary cancer between 1998 and 2020 (California Cancer Registry Data).
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Figure 1 shows the cumulative incidence over time of developing subsequent malignant neoplasm (SMN) among survivors of primary adolescent and young adult (AYA) (a) female breast cancer who developed lung (n = 112) and non-lung (n = 4,971) SMN, (b) cervical/uterine cancer who developed lung (n = 95) and non-lung (n = 1,451) SMN, (c) Hodgkin lymphoma who developed lung (n = 70) and non-lung (n = 1,129) and who were diagnosed with a primary cancer between 1998 and 2020 (California Cancer Registry Data).
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Table 3 shows vital status and cause of death by subsequent malignant neoplasm status.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Table 3 shows vital status and cause of death by subsequent malignant neoplasm status.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Table 1 shows the frequency of subsequent malignant neoplasms after primary cancer.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Supplemental Table 1 shows the frequency of subsequent malignant neoplasms after primary cancer.
- Open Access
- 15 July 2025
- Published by Elsevier in Environmental Research
- Vol. 285 (Pt 1) , 122335
Agricultural copper pesticide exposure and DNA methylation in Central Valley of California residents with and without Parkinson's disease
- 15 July 2025
- Published by Elsevier in Environmental Research
- Vol. 285 (Pt 1) , 122335
Open AccessAgricultural copper pesticide exposure and DNA methylation in Central Valley of California residents with and without Parkinson's disease
- 24 June 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (9) , 1618-1626
Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Background: Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized. Methods: Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry (n = 251,632). Pearson’s χ2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN. Results: A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither. Conclusions: Lung SMN has a long latency and high mortality among survivors of AYA cancer. Impact: More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
- 24 June 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (9) , 1618-1626
Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study
Background: Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized. Methods: Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry (n = 251,632). Pearson’s χ2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN. Results: A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither. Conclusions: Lung SMN has a long latency and high mortality among survivors of AYA cancer. Impact: More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
- Open Access
- 9 May 2025
- Published by Elsevier in Environment International
- Vol. 200, 109526
Exploring the link between grandmaternal air pollution exposure and Grandchild’s ASD risk: A multigenerational population-based study in California
- 9 May 2025
- Published by Elsevier in Environment International
- Vol. 200, 109526
Open AccessExploring the link between grandmaternal air pollution exposure and Grandchild’s ASD risk: A multigenerational population-based study in California